- Home
- LCTX vs QSI Comparison
LCTX vs QSI Comparison
Compare LCTX & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- QSI
- Stock Information
- Founded
- LCTX 1990
- QSI 2013
- Country
- LCTX United States
- QSI United States
- Employees
- LCTX N/A
- QSI N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- QSI Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- QSI Health Care
- Exchange
- LCTX Nasdaq
- QSI Nasdaq
- Market Cap
- LCTX 274.0M
- QSI 226.8M
- IPO Year
- LCTX N/A
- QSI N/A
- Fundamental
- Price
- LCTX $1.44
- QSI $1.49
- Analyst Decision
- LCTX Strong Buy
- QSI Strong Buy
- Analyst Count
- LCTX 4
- QSI 3
- Target Price
- LCTX $4.25
- QSI $2.38
- AVG Volume (30 Days)
- LCTX 1.2M
- QSI 5.6M
- Earning Date
- LCTX 11-13-2025
- QSI 11-11-2025
- Dividend Yield
- LCTX N/A
- QSI N/A
- EPS Growth
- LCTX N/A
- QSI N/A
- EPS
- LCTX N/A
- QSI N/A
- Revenue
- LCTX $10,914,000.00
- QSI $3,412,000.00
- Revenue This Year
- LCTX N/A
- QSI N/A
- Revenue Next Year
- LCTX $176.00
- QSI $219.33
- P/E Ratio
- LCTX N/A
- QSI N/A
- Revenue Growth
- LCTX 76.43
- QSI 100.47
- 52 Week Low
- LCTX $0.37
- QSI $0.61
- 52 Week High
- LCTX $1.42
- QSI $5.77
- Technical
- Relative Strength Index (RSI)
- LCTX 69.73
- QSI 64.26
- Support Level
- LCTX $1.20
- QSI $1.24
- Resistance Level
- LCTX $1.42
- QSI $1.16
- Average True Range (ATR)
- LCTX 0.07
- QSI 0.09
- MACD
- LCTX 0.01
- QSI 0.05
- Stochastic Oscillator
- LCTX 91.67
- QSI 96.81
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.